Isofol's board appoints Thomas Andersson as new CEO of the company
Gothenburg, Sweden, February 28, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the board of Isofol has decided to appoint Thomas Andersson as CEO of the company from February 28, 2023. As a consequence of this decision, the current CEO, Ulf Jungnelius, is resigning and is now being dismissed from his position.Thomas Andersson (b. 1952) has long experience from leading positions in the pharmaceutical industry, including as CEO of Spectracure, Senior Advisor at Karolinska Institutet Innovations AB, Investment Manager at Karolinska Development AB, CEO of